证券代码：002653 证券简称：海思科 公告编号：2025-102 海思科医药集团股份有限公司 关于 1 类创新药安瑞克芬注射液 新适应症获批的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）于近日收到 国家药品监督管理局下发的 1 类创新药安瑞克芬注射液（商品名称： 思舒静®，研发代号：HSK21542）《药品注册证书》，现将相关情况 公告如下： 一、 药品及申请基本信息 药品名称：安瑞克芬注射液 适 应 症：本品用于维持性血液透析的慢性肾脏疾病相关中重度 瘙痒成人患者。 特此公告。 2 审批结论：根据《中华人民共和国药品管理法》及有关规定，经 审查，本品符合药品注册的有关要求，批准增加适应症，新增适应症 为"治疗成人维持性血液透析患者的慢性肾脏疾病相关的中度至重 度瘙痒"，发给药品注册证书。 二、 研发项目简介 HSK21542 是我司自主研发的高选择性外周 kappa 阿片受体（κ Opioid Receptor，KOR）激动剂。临床研究结果表明，HSK21542 注 射液能显著缓解瘙痒，主要疗效指标 ...

Core Viewpoint - The company Haisco (002653.SZ) has received approval from the National Medical Products Administration for its innovative drug Anruikefen injection, which now includes a new indication for treating moderate to severe itching associated with chronic kidney disease in adult patients undergoing maintenance hemodialysis [1] Group 1 - The newly approved indication for Anruikefen injection will be included in the priority review and approval process starting from July 2024 [1] - Anruikefen injection was first approved in May 2025 for the indication of treating mild to moderate pain after abdominal surgery [1] - Phase III clinical trials for the indication of postoperative analgesia in orthopedic surgery are currently progressing smoothly [1]

Group 1 - Yihau New Materials plans to reduce its shareholding by up to 1% of the company's total shares, amounting to 165,500 shares, due to personal funding needs [1] - Fuxing Pharmaceutical's subsidiary has received approval for a new indication for its drug, which is used in the treatment of certain types of breast cancer [1][2] - Shantui Co. has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [3] Group 2 - Sierte's chairman plans to increase his shareholding by an amount between 3 million to 6 million yuan [4] - Borui Pharmaceutical's BGM0504 tablet has received approval for clinical trials in overweight and obese adults [5] - Ganyue Expressway reported vehicle toll service revenue of 349 million yuan for August [6] Group 3 - Chip Microelectronics has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [7] - Lingrui Pharmaceutical's director plans to reduce his shareholding by up to 200,000 shares, representing 0.0353% of the total shares [8] - Jiahu Energy has adjusted its share repurchase price limit to 11.63 yuan per share [10] Group 4 - Spring Airlines reported a year-on-year increase of 12.23% in passenger turnover for August [11] - Kaida has received an invention patent for a self-calibrating sensor technology [12] - Chuanheng Co. has obtained a new utility model patent aimed at improving industrial waste utilization [14] Group 5 - Huashi Technology received a government subsidy of 2.21 million yuan, accounting for 22.71% of its latest audited net profit [15] - Shanghai Pharmaceuticals' controlling shareholder plans to increase its H-share holdings by up to 74 million shares [16] - Hongrun Construction has won a bid for a significant segment of the Shanghai Metro Line 21 project, valued at 126 million yuan [18] Group 6 - Sanfangxiang plans to invest 100 million yuan to establish a wholly-owned subsidiary focused on green technology [19] - Lao Fengxiang's subsidiaries plan to jointly invest in luxury goods sales and gold refining companies [20][21] - China Eastern Airlines reported an 8.72% year-on-year increase in passenger turnover for August [22] Group 7 - Inner Mongolia First Machinery has signed a railway freight car procurement contract worth 186 million yuan [22] - Jiuqiang Bio has received five invention patents related to diagnostic reagents [24] - Longmag Technology plans to invest 210 million yuan in its second phase project in Vietnam [25] Group 8 - Galaxy Magnetics plans to acquire 100% equity of Kyoto Longtai, with its stock suspended for trading [26] - Jinlong Co.'s controlling shareholder will have 30 million shares auctioned [27] - Haishi Co.'s controlling shareholder has released the pledge on 29.97 million shares [28] Group 9 - Qiu Tianwei plans to reduce its shareholding by up to 1.17% of the total shares [29] - Xiaocheng Technology's directors plan to reduce their shareholding by a total of 0.08% [30] - Victory Co. reported that Sunshine Life Insurance has reduced its shareholding by 4.4 million shares [31] Group 10 - Xindong Technology plans to distribute a cash dividend of 0.156 yuan per share [32] - Huaqin Technology plans to distribute a cash dividend of 0.13 yuan per share [33] - Kexing Pharmaceutical's controlling shareholder intends to transfer 5% of the company's shares [35] Group 11 - Guojin Securities has completed the repayment of its second short-term financing bond for 1.0205 billion yuan [38] - Chunhui Intelligent Control's application for asset acquisition has been accepted by the Shenzhen Stock Exchange [39] - Chaohongji has submitted its H-share issuance application to the Hong Kong Stock Exchange [40] Group 12 - Tianyue Advanced has fully exercised its over-allotment option, involving 716,180 H-shares [40] - Chengfeng Technology's vice president has resigned due to internal adjustments [41] - Yingpais plans to establish a 100 million yuan technology sports industry investment fund [43]

Core Viewpoint - The stock of Haishike experienced a decline of 2.03% on September 15, 2023, with a current price of 56.90 CNY per share and a total market capitalization of 63.723 billion CNY, despite a year-to-date increase of 72.53% [1] Financial Performance - For the first half of 2025, Haishike reported a revenue of 2.001 billion CNY, representing a year-on-year growth of 18.63%, while the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2] - Cumulative cash dividends since the A-share listing amount to 3.673 billion CNY, with 687 million CNY distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 25.93% to 11,400, with an average of 42,147 circulating shares per shareholder, down by 28.64% [2] - The top ten circulating shareholders include several funds, with notable increases in holdings by China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002653 证券简称：海思科 公告编号：2025-100 海思科医药集团股份有限公司 关于控股股东部分股份 解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 海思科医药集团股份有限公司（以下简称"公司"）于近日接到公司控股股东及实际控制人王俊民先生的 通知，获悉王俊民先生所持有本公司的部分股份已解除质押，具体事项如下： 一、股东股份解除质押的基本情况 海思科医药集团股份有限公司 ■ 二、股东股份累计质押的情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： ■ 三、备查文件 中国证券登记结算有限责任公司证券质押及司法冻结明细表。 特此公告。 董事会 2025年9月15日 证券代码：002653 证券简称：海思科公告编号：2025-101 海思科医药集团股份有限公司 关于控股股东之一致行动人权益变动 触及1%及5%整数倍的提示性公告 股东申萍、王俊民保证向公司提供的信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 本公司及董事会全体成员保证公告内容与信 ...

本次权益变动后，申萍与其一致行动人王俊民合计持有公司股份由449,176,294股减少至447,926,294股， 合计持股比例由40.11%减少至40.00%，变动后比例触及1%及5%的整数倍。 格隆汇9月14日丨海思科(002653.SZ)公布，近日，公司收到控股股东之一致行动人申萍《关于减持公司 股份的告知函》，获悉申萍于2025年9月1日—2025年9月12日期间以集中竞价方式减持公司股份125万 股，占公司总股本的0.11%。 ...

海思科医药集团股份有限公司 简式权益变动报告书 上市公司名称：海思科医药集团股份有限公司 股票简称：海思科 股票代码：002653 股票上市地点：深圳证券交易所 信息披露义务人1：王俊民 信息披露义务人2：申萍 签署日期：二〇二五年九月 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办法》 《公开发行证券的公司信息披露内容与格式准则第15号——权益变动报告书》及 相关法律法规编写本权益变动报告书(以下简称"本报告书")。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第15号——权益变动报告书》的规定，本报告 书已全面披露信息披露义务人在海思科医药集团股份有限公司拥有权益的股份 变动情况。 四、截至本报告书签署之日，除本报告书披露的持股信息外，信息披露义务人没 有通过任何其他方式增加或减少其在海思科医药集团股份有限公司拥有权益的 股份。 五、本次权益变动是根据本报告书所载明的资料进行的，除信息披露义务人 外，没有委托或者授权任何其他人提供未在本报告书中列载的信息和对本报告书 做出任何 ...

证券代码：002653 证券简称：海思科 公告编号：2025-101 海思科医药集团股份有限公司 关于控股股东之一致行动人权益变动 触及 1%及 5%整数倍的提示性公告 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信 息一致。 特别提示： 1、本次权益变动系控股股东之一致行动人申萍女士减持，不会导致海思科 医药集团股份有限公司(以下简称"公司")的控股股东和实际控制人发生变化， 亦不会对公司日常经营管理产生影响； 2、本次权益变动后，申萍女士与其一致行动人王俊民先生合计持有公司股 份由 449,176,294 股减少至 447,926,294 股，合计持股比例由 40.11%减少至 40.00%，变动后比例触及 1%及 5%的整数倍。 3、本次减持事项已按照有关规定进行了预披露，本次实际减持情况与此前 披露的意向、承诺及减持计划一致。 股东申萍、王俊民保证向公司提供的信息披露内容的真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 公司于 2025 年 7 月 26 日披露了《关于控股股东之一致行动人股 份减持计划的预披露公告》(公告编号：2025-086)，控股股东之一致 行动人申萍女士（ ...

下： 证券代码：002653 证券简称：海思科 公告编号：2025-100 海思科医药集团股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）于近日接到 公司控股股东及实际控制人王俊民先生的通知，获悉王俊民先生所持 有本公司的部分股份已解除质押，具体事项如下： 二、股东股份累计质押的情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如 2 | | 持股 | | | 合计占 | 合计占 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | | 持股 | 累计质押数 | 其所持 | 公司总 | | | | | | 名称 | 数量 （万股） | 比例 | 量（万股） | 股份比 | 股本比 | 已质押股 | 占已 | 未质押股 | 占未 | | | | | | 例 | 例 | 份限售和 | 质押 | 份限售和 | 质押 | 1 股东 ...

Core Insights - Complement drugs are specifically designed to treat diseases related to abnormal activation or suppression of the complement system, with a complex development history that faced significant challenges until the first drug, Soliris, was approved in 2007 [1][4] - The market for complement drugs is expanding rapidly, with a projected global market size of $8.179 billion in 2024, reflecting a year-on-year growth of 23.4%, primarily driven by advancements in treatment for eye diseases [1][6] - The leading complement drugs in the market are AstraZeneca's C5 antibodies, Soliris and Ultomiris, which together are expected to account for 79.6% of total sales in 2024 [1][6][7] Industry Overview - The complement drug industry has evolved to include over ten approved drugs, utilizing various forms such as monoclonal antibodies, small molecule inhibitors, cyclic peptides, and nucleic acid aptamers, indicating a diverse technological landscape [1][4] - The expansion of indications from rare blood diseases to more common conditions signifies a maturation in the development of complement drugs, with ongoing research opening new therapeutic areas [1][4][8] Market Dynamics - The sales of Ultomiris are projected to grow significantly, from $339 million in 2019 to $3.924 billion in 2024, surpassing Soliris, which is expected to see a decline in sales by 17.7% to $2.588 billion in 2024 [7] - Domestic companies such as Heng Rui Medicine and Hai Si Ke are actively entering the complement drug market, with over ten clinical trials registered in China, primarily focusing on IgA nephropathy [1][8] Future Trends - The competition in the complement drug market is expected to intensify with the introduction of more drugs, emphasizing technological innovation and cost reduction to enhance accessibility [8] - There is a growing focus on multi-target and combination therapy strategies, which may improve treatment efficacy and reduce side effects, as well as an expansion of applications to include more rare and autoimmune diseases [8]